New-Onset Psoriatic Arthritis under Biologics in Psoriasis Patients: An Increasing Challenge?
Psoriasis and psoriatic arthritis (PsA) development is sustained by tumor necrosis factor (TNF)α, interleukin (IL)17, and IL23; hence, biologics targeting those cytokines represent useful therapeutic weapons for both conditions. Nevertheless, biologics strongly reduce PsA risk; several studies repor...
| Main Authors: | , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2021-10-01
|
| Series: | Biomedicines |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2227-9059/9/10/1482 |
| _version_ | 1827680015327690752 |
|---|---|
| author | Matteo Megna Sonia Sofia Ocampo-Garza Luca Potestio Giuseppina Fontanella Lucia Gallo Sara Cacciapuoti Angelo Ruggiero Gabriella Fabbrocini |
| author_facet | Matteo Megna Sonia Sofia Ocampo-Garza Luca Potestio Giuseppina Fontanella Lucia Gallo Sara Cacciapuoti Angelo Ruggiero Gabriella Fabbrocini |
| author_sort | Matteo Megna |
| collection | DOAJ |
| description | Psoriasis and psoriatic arthritis (PsA) development is sustained by tumor necrosis factor (TNF)α, interleukin (IL)17, and IL23; hence, biologics targeting those cytokines represent useful therapeutic weapons for both conditions. Nevertheless, biologics strongly reduce PsA risk; several studies reported the possibility of new-onset PsA during biologic therapy for psoriasis. The aim of this 1-year prospective study is to evaluate the prevalence of paradoxical PsA in psoriasis patients under biologic therapy and review the existing literature. For each patient, age, sex, psoriasis duration, psoriasis severity, comorbidities, and previous and current psoriasis treatments were collected, and each subject was screened for PsA using the Early ARthritis for Psoriatic patient (EARP) questionnaire every 3 months for 1 year. New-onset PsA was diagnosed in 10 (8.5%) out of 118 patients (three male, 30.0%; mean age 44.5 years) involving every different biologic class (anti-TNF, anti-IL12/23, anti-IL17, and anti-IL23). No significant risk factor for new-onset PsA was identified; no significant difference was found comparing patients who developed PsA and subjects who did not develop PsA regarding psoriasis severity, past/current therapies, and comorbidities. Clinicians must keep in mind the possibility of PsA onset also in patients undergoing biologics so that PsA screening should be strongly recommended at each follow-up. |
| first_indexed | 2024-03-10T06:42:06Z |
| format | Article |
| id | doaj.art-115cfb119ce7462dbf4ad4a087e65c64 |
| institution | Directory Open Access Journal |
| issn | 2227-9059 |
| language | English |
| last_indexed | 2024-03-10T06:42:06Z |
| publishDate | 2021-10-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Biomedicines |
| spelling | doaj.art-115cfb119ce7462dbf4ad4a087e65c642023-11-22T17:32:37ZengMDPI AGBiomedicines2227-90592021-10-01910148210.3390/biomedicines9101482New-Onset Psoriatic Arthritis under Biologics in Psoriasis Patients: An Increasing Challenge?Matteo Megna0Sonia Sofia Ocampo-Garza1Luca Potestio2Giuseppina Fontanella3Lucia Gallo4Sara Cacciapuoti5Angelo Ruggiero6Gabriella Fabbrocini7Section of Dermatology, Department of Clinical Medicine and Surgery, University of Naples Federico II, Via Pansini 5, 80131 Napoli, ItalySection of Dermatology, Department of Clinical Medicine and Surgery, University of Naples Federico II, Via Pansini 5, 80131 Napoli, ItalySection of Dermatology, Department of Clinical Medicine and Surgery, University of Naples Federico II, Via Pansini 5, 80131 Napoli, ItalySection of Dermatology, Department of Clinical Medicine and Surgery, University of Naples Federico II, Via Pansini 5, 80131 Napoli, ItalySection of Dermatology, Department of Clinical Medicine and Surgery, University of Naples Federico II, Via Pansini 5, 80131 Napoli, ItalySection of Dermatology, Department of Clinical Medicine and Surgery, University of Naples Federico II, Via Pansini 5, 80131 Napoli, ItalySection of Dermatology, Department of Clinical Medicine and Surgery, University of Naples Federico II, Via Pansini 5, 80131 Napoli, ItalySection of Dermatology, Department of Clinical Medicine and Surgery, University of Naples Federico II, Via Pansini 5, 80131 Napoli, ItalyPsoriasis and psoriatic arthritis (PsA) development is sustained by tumor necrosis factor (TNF)α, interleukin (IL)17, and IL23; hence, biologics targeting those cytokines represent useful therapeutic weapons for both conditions. Nevertheless, biologics strongly reduce PsA risk; several studies reported the possibility of new-onset PsA during biologic therapy for psoriasis. The aim of this 1-year prospective study is to evaluate the prevalence of paradoxical PsA in psoriasis patients under biologic therapy and review the existing literature. For each patient, age, sex, psoriasis duration, psoriasis severity, comorbidities, and previous and current psoriasis treatments were collected, and each subject was screened for PsA using the Early ARthritis for Psoriatic patient (EARP) questionnaire every 3 months for 1 year. New-onset PsA was diagnosed in 10 (8.5%) out of 118 patients (three male, 30.0%; mean age 44.5 years) involving every different biologic class (anti-TNF, anti-IL12/23, anti-IL17, and anti-IL23). No significant risk factor for new-onset PsA was identified; no significant difference was found comparing patients who developed PsA and subjects who did not develop PsA regarding psoriasis severity, past/current therapies, and comorbidities. Clinicians must keep in mind the possibility of PsA onset also in patients undergoing biologics so that PsA screening should be strongly recommended at each follow-up.https://www.mdpi.com/2227-9059/9/10/1482psoriasispsoriatic arthritisbiologic therapiesparadoxical reactionanti-TNFanti-IL12/23 |
| spellingShingle | Matteo Megna Sonia Sofia Ocampo-Garza Luca Potestio Giuseppina Fontanella Lucia Gallo Sara Cacciapuoti Angelo Ruggiero Gabriella Fabbrocini New-Onset Psoriatic Arthritis under Biologics in Psoriasis Patients: An Increasing Challenge? Biomedicines psoriasis psoriatic arthritis biologic therapies paradoxical reaction anti-TNF anti-IL12/23 |
| title | New-Onset Psoriatic Arthritis under Biologics in Psoriasis Patients: An Increasing Challenge? |
| title_full | New-Onset Psoriatic Arthritis under Biologics in Psoriasis Patients: An Increasing Challenge? |
| title_fullStr | New-Onset Psoriatic Arthritis under Biologics in Psoriasis Patients: An Increasing Challenge? |
| title_full_unstemmed | New-Onset Psoriatic Arthritis under Biologics in Psoriasis Patients: An Increasing Challenge? |
| title_short | New-Onset Psoriatic Arthritis under Biologics in Psoriasis Patients: An Increasing Challenge? |
| title_sort | new onset psoriatic arthritis under biologics in psoriasis patients an increasing challenge |
| topic | psoriasis psoriatic arthritis biologic therapies paradoxical reaction anti-TNF anti-IL12/23 |
| url | https://www.mdpi.com/2227-9059/9/10/1482 |
| work_keys_str_mv | AT matteomegna newonsetpsoriaticarthritisunderbiologicsinpsoriasispatientsanincreasingchallenge AT soniasofiaocampogarza newonsetpsoriaticarthritisunderbiologicsinpsoriasispatientsanincreasingchallenge AT lucapotestio newonsetpsoriaticarthritisunderbiologicsinpsoriasispatientsanincreasingchallenge AT giuseppinafontanella newonsetpsoriaticarthritisunderbiologicsinpsoriasispatientsanincreasingchallenge AT luciagallo newonsetpsoriaticarthritisunderbiologicsinpsoriasispatientsanincreasingchallenge AT saracacciapuoti newonsetpsoriaticarthritisunderbiologicsinpsoriasispatientsanincreasingchallenge AT angeloruggiero newonsetpsoriaticarthritisunderbiologicsinpsoriasispatientsanincreasingchallenge AT gabriellafabbrocini newonsetpsoriaticarthritisunderbiologicsinpsoriasispatientsanincreasingchallenge |